Information om | Engelska ordet IPILIMUMAB

Exempel på hur man kan använda IPILIMUMAB i en mening

• Therapies for metastatic melanoma include the biologic immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib.
• The blocking antibody ipilimumab has been effectively used in the clinical treatment of melanoma, RCC, and NSCLC with some degree of success.
• Also using anti-CTLA4 antibody, this axis was significantly up-regulated in pretreatment melanoma lesions in patients with good clinical response after ipilimumab administration.
• Therapies for metastatic melanoma include the biological immunotherapy agents ipilimumab, pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and an MEK inhibitor trametinib.
• Bristol Myers Squib (Investigator initiated clinical trial): Evaluation of concurrent ipilimumab therapy and radiosurgery for oligometastatic but unresectable malignant melanoma.
• Current clinical trials combine Urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab (NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma.
• “SAA funding has played a major role in clinically developing the four FDA approved immunotherapy medicines ipilimumab (YERVOY), nivolumab (OPDIVO), pembrolizumab (KEYTRUDA) and atezolizumab (TECENTRIQ).
• In contrast, the combination of immunomodulatory drugs such as ipilimumab and pembrolizumab can partially reconstitute systemic anti-tumor immune reactions induced after local tumor radiotherapy.
• As of 2016, talimogene laherparepvec has been studied in early stage clinical trials in pancreatic cancer, soft-tissue sarcoma, and head and neck squamous-cell carcinoma; it had also been tested in combination with checkpoint inhibitors ipilimumab and pembrolizumab.
• Two thirds of the participants were treated with tebentafusp and one third of the participants were treated with comparator drugs based on investigators' choice that included pembrolizumab, ipilimumab, or dacarbazine.
• The only oligoclonal antibody treatment against immune checkpoint currently approved is the cocktail of nivolumab (anti-PD1 antibody) and ipilimumab (anti-CTLA-4 antibody).

Förberedelsen av sidan tog: 646,58 ms.